Thermo Fisher Scientific Collaborates to Introduce Fully Automated Cell Line Automation Platform

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, March 2023
Volume 18
Issue 3

Thermo Fisher and Celltrio are introducing a new automation platform to address critical scale-up challenges in biotherapeutics.

Thermo Fisher Scientific and Celltrio announced on Feb. 6, 2022 their collaboration to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the critical unmet market need for high-throughput automated cell line culturing and maintenance.

Thermo Fisher will also immediately take on exclusive responsibility for sales, installation, and support of the RoboCell system in Europe. Celltrio’s RoboCell systems distributed in Europe will now use Momentum software for work scheduling and date management.

“Cell line scale-up challenges have long stifled the full potential of biotherapy research. While researchers have been able to automate some aspects of cell line production, full automation has been well out of reach,” said Hansjoerg Haas, senior director and general manager, laboratory automation, Thermo Fisher Scientific, in a company press release. “By collaborating with Celltrio, we’re bringing together the capabilities that make fully automated cell line culturing a reality. With the ability to effectively scale processes, biotherapeutics customers can focus on getting their innovative therapies to patients, paving the way to a better, healthier world.”
Source: Thermo Fisher

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content